Lapatinib ditasylate monohydrate
We are a manufacturer based in China, specializing in high-quality Lapatinib ditasylate monohydrate for industrial clients worldwide. Technical support and custom formulation available.
Category：Active Pharmaceutical Ingredients | Brand：MT
Factory Direct
7-30 Days Lead Time
MOQ: 100KG
Global Export
Introduction
Catalog ID80071749
CAS NO.388082-78-8
Purity 98%
Colecular formula C29H26ClFN4O4S.2C7H8O3S.H2O
Molecular weight 943.46
Melting point: >276°C
| Category | Content |
|---|---|
| Generic Name | Lapatinib Ditosylate Monohydrate |
| Chemical Formula | C43H44ClFN4O11S3 |
| CAS Number | 388082-78-8 |
| Mechanism of Action | Lapatinib Ditosylate Monohydrate is a dual inhibitor of EGFR and ErbB-2 tyrosine kinases, with IC50 values of 10.8 nM and 9.2 nM, respectively. It induces cell cycle arrest in the G1 phase and inhibits tumor growth. |
| Indications | – Used for the treatment of advanced breast cancer.<br>- Investigated for other solid tumors. |
| Dosage Forms | Tablets (250 mg, 500 mg) |
| Administration | – Usual dose: 1250 mg orally once daily.<br>- Take with or without food. |
| Common Side Effects | – Diarrhea.<br>- Nausea.<br>- Vomiting.<br>- Fatigue.<br>- Rash. |
| Serious Side Effects | – Liver toxicity.<br>- Cardiotoxicity.<br>- Interstitial lung disease. |
| Precautions | – Monitor liver function regularly.<br>- Use with caution in patients with liver impairment.<br>- Inform your doctor if pregnant or breastfeeding. |
| Storage | Store at -25 to -15°C. |
| Developer | GlaxoSmithKline (GSK) |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
Inquiry
We'll reply within 24 hours
Or contact us directly:
